Mary Wilson
Well-known member
AUGUST 19, 2020
By ADAM FEUERSTEIN and DAMIAN GARDE
Back before remdesivir became a household name, Gilead Sciences’ most-discussed drug was filgotinib, a treatment for inflammatory disease expected to deliver billions of dollars in new revenue at a time when the biotech desperately needs it. All that got put in jeopardy on Tuesday night.
The FDA rejected Gilead’s application to sell filgotinib as a treatment for rheumatoid arthritis and said it wouldn’t reconsider until the company can provide more data on the drug’s effect on patients’ sperm counts.
https://www.statnews.com/2020/08/19/expected-blockbuster-gilead-drug-rejected-imperiling-biotech-growth/
By ADAM FEUERSTEIN and DAMIAN GARDE
Back before remdesivir became a household name, Gilead Sciences’ most-discussed drug was filgotinib, a treatment for inflammatory disease expected to deliver billions of dollars in new revenue at a time when the biotech desperately needs it. All that got put in jeopardy on Tuesday night.
The FDA rejected Gilead’s application to sell filgotinib as a treatment for rheumatoid arthritis and said it wouldn’t reconsider until the company can provide more data on the drug’s effect on patients’ sperm counts.
https://www.statnews.com/2020/08/19/expected-blockbuster-gilead-drug-rejected-imperiling-biotech-growth/